Powered by
FARMINGTON HILLS—Ocuphire Pharma Inc., a startup pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, announced statistically significant and clinically …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-fighting drugs, announced that its lead drug candidate, bempedoic acid, was included in the …
GRAND RAPIDS—The Grand Rapids-based pharmaceutical startup Tetra Therapeutics announced that new preclinical research suggests the ability of its investigational drug, BPN14770, to protect against memory loss and neuronal atrophy induced …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), the Ann Arbor-based developer of a new class of cholesterol-reducing drugs, announced that the compensation committee of its board of directors granted non-qualified stock …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), the Ann Arbor pharma startup developing a new class of cholesterol-fighting drugs, announced positive top-line results from a Phase 2 clinical study of its combination …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical startup that’s about to introduce a new class of cholesterol-fighting drugs, reported a loss of $54.2 million or $2.01 a share …
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging to consumers for the pharmaceutical industry, reported net income of $406,617 or 3 cents a share, up 45 percent in …
GRAND RAPIDS—Tetra Discovery Partners, a clinical-stage biotechnology company, announced the company’s name change to Tetra Therapeutics. The name change reflects the company’s transition from a company focused on discovery research …
FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing. …
ANN ARBOR—Officials at Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR), a pharmaceutical startup developing a new class of cholesterol-lowering drugs, announced a $200 million funding agreement with an investor group …